Pharmacology and PKPD of Antihypertensives

5.0(1)
studied byStudied by 8 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/129

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 10:27 PM on 12/16/24
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai

No analytics yet

Send a link to your students to track their progress

130 Terms

1
New cards

How do diuretics work to lower BP?

Lower BP by depleting the body of sodium and reducing blood volume

2
New cards

How do antihypertensives that block RAAS lower BP?

Reduce total vascular resistance and may reduce blood volume

3
New cards

How do direct vasodilators lower BP?

Relaxing vascular smooth muscle leads to arterial vasodilation. Decreasing systemic vascular resistance.

4
New cards

How do sympatholytic agents work to lower bp?

Decrease BP by decreasing sympathetic input and/or increase parasympathetic input

5
New cards

Examples of diuretic drug classes:

Thiazide diuretics, loop diuretics, mineralocorticoid (aldosterone) receptor antagonists, potassium-sparing diuretics

6
New cards

Examples of drug classifications that block RAAS:

ACEi, ARB, direct renin inhibitors

7
New cards

Examples of direct vasodilators:

Calcium channel blockers, hydralazine, minoxidil

8
New cards

Examples of sympatholytic agents:

Beta-blockers, clonidine

9
New cards

What drug classes are first-line antihypertensives?

Thiazide diuretics, ACEi, ARB, calcium channel blockers

10
New cards

How much can diuretics lower BP?

Can lower BP up to 10-15 mmHg in most patients

11
New cards

Are diuretics used as monotherapy?

Can be used as monotherapy for mild hypertension, but are often used in combination with other agents

12
New cards

Brand name of Chlorthalidone?

Hygroton, Thalitone

13
New cards

Brand name of Indapamide?

Lozol

14
New cards

Brand name of Metolazone?

Zaroxolyn

15
New cards

Indication for thiazide diuretics?

First-line antihypertensive

16
New cards

MOA for thiazide diuretics:

Increases sodium (and therefore water) and chloride excretion by blocking reabsorption in the distal convoluted tubule of the nephron by blocking the Na+/Cl- transporter (NCC)

17
New cards

CI for thiazide diuretics

Hypersensitivity to sulfonamides (low risk of cross-reactivity with antibiotics), anuria

18
New cards

ADRs for thiazide diuretics

Dizziness, hyperuricemia, other electrolyte abnormalities (hyponatremia, hypokalemia, hypomagnesemia, hypercalcemia), pancreatitis

19
New cards

Key PKPD for thiazide diuretics

Secreted by the organic acid secretory system in the proximal tubule which completes with secretion of uric acid which can elevate levels of uric acid

20
New cards

Pearls for thiazide diuretics

Not as effective if CrCl < 30 mL/min (prefer chlorthalidone)

21
New cards

Brand name of furosemide

Lasix

22
New cards

Indication for loop diuretics

Edema due to heart failure, hypertension

23
New cards

MOA for loop diuretics

Actively secreted via the nonspecific organic acid transport system into the lumen of the thick ascending limb of Henle’s loop, where it decreases sodium reabsorption by competing for the chloride site on the Na+-K+-2Cl- cotransporter

24
New cards

CI for loop diuretics

Anuria (no urine)

25
New cards

ADRs for loop diuretics

Hyperuricemia, hypokalemia, hypomagnesemia, dizziness, acute kidney injury (AKI), ototoxicity

26
New cards

DDI for loop diuretics

increased risk of ototoxicity if used with aminoglycosides

27
New cards

Pearls for loop diuretics

Most efficacious diuretics (causes most fluid removal)

28
New cards

BBW for loop diuretics:

Potent diuretic, at high doses can lead to profound fluid and electrolyte loss

29
New cards

Bioavailability of furosemide?

~40-70%

30
New cards

Duration for furosemide?

4-8 hours

31
New cards

Half-life for furosemide?

1-2 hours

32
New cards

Elimination of furosemide

mainly renal

33
New cards

Bioavailability for torsemide

~90%

34
New cards

Duration of torsemide

8-12 hours

35
New cards

Half-life of torsemide

3.5 hours

36
New cards

Elimination of torsemide

mainly hepatic

37
New cards

Bioavailability of bumetanide

~90%

38
New cards

Duration of bumetanide

3-6 hours

39
New cards

Half-life of bumetanide

1-1.5 hours

40
New cards

Elimination of bumetanide

50% renal and 50% hepatic

41
New cards

Bioavailability of ethacrynic acid

100%

42
New cards

Duration for ethacrynic acid

IV: 2-4 hours

PO: 12 hours

43
New cards

Half-life of ethacrynic acid

2-4 hours

44
New cards

Elimination of ethacrynic acid

renal

45
New cards

Brand name of torsemide

Demadex

46
New cards

Brand name of bumetanide?

Bumex

47
New cards

Brand name of spironolactone

Aldactone, CaroSpir

48
New cards

Brand name of eplerenone

Inspra

49
New cards

Indication for MRAs?

Heart failure, HTN

50
New cards

MOA for MRAs?

Competes with aldosterone for receptor sites in the distal renal tubules, increasing sodium chloride and water excretion while conserving potassium and hydrogen ions; may block the effect of aldosterone on arteriolar smooth muscle as well.

51
New cards

CI for MRAs?

Anuria (no urine) and hyperkalemia

52
New cards

ADRs for MRAs?

Dehydration, hyperkalemia, hyponatremia, dizziness, cardiac arrhythmias due to electrolyte abnormalities

53
New cards

Specific ADRs for spironolactone:

Gynecomastia, breast tenderness, impotence

54
New cards

Specific ADRs for eplereone?

increased triglycerides

55
New cards

Key PKPD for MRAs?

Spironolactone binds with high affinity to the androgen receptor which is the source of ADRs like gynecomastia and decreased libido.

Eplerenone has a much greater selectivity for mineralocorticoid receptor

56
New cards

DDI for MRAs?

Eplerenone: strong CYP3A4 inhibitors will increase concentrations

57
New cards

Pearls of MRAs?

Minimally efficacious blood pressure control when used as monotherapy

58
New cards

What are MRAs also known as?

Aldosterone antagonists (‘aldo’)

59
New cards

Examples of potassium-sparing diuretics:

Triamterene, amiloride

60
New cards

Indication for potassium-sparing diuretics

Hypertension

61
New cards

MOA for potassium-sparing diuretics

Competitive inhibition of epithelial sodium channel (ENaC) in the collecting duct of the nephron —→ decrease sodium reabsorption and increase potassium reabsorption.

62
New cards

CI for potassium-sparing diuretics

Hypersensitivity to sulfonamides (low risk of cross-reactivity with antibiotics), anuria

63
New cards

ADRs for potassium sparing diuretics

Hyperkalemia, hypotension, dizziness, headache, gout, SJS

64
New cards

Key PKPD for potassium sparing diuretics

Amiloride has longer duration of action than triamterene (24 hours vs 8 hours)

65
New cards

Pearls of potassium-sparing diuretics

Almost always in a combination tablet to decrease rates of hypokalemia with thiazide diuretics

66
New cards

Brand name of lisinopril

Prinivil, Zestril

67
New cards

Indication for ACEi

First-line antihypertensive

Other: MI, heart failure with reduced ejection fraction (HFrEF)

68
New cards

MOA for ACEi

Competitive angiotensin converting enzyme inhibitor (ACEi). This prevents stimulation of the angiotensin II receptor. The angiotensin II receptor is responsible for vasoconstriction, aldosterone secretion, sympathetic outflow, and stimulation of renal sodium reabsorption

69
New cards

CI for ACEi

History of ACEi-induced, hereditary, or idiopathic angioedema, pregnancy

70
New cards

ADRs for ACEi

Hyperkalemia, Acute kidney Injury (AKI), dizziness, dry cough, angioedema, liver failure

71
New cards

Key PKPD for ACEi

Almost all ACEi are renally eliminated.

By inhibiting peptidyl dipeptidase (hydrolyzes angiotensin I —> II), the breakdown of bradykinin is also inhibited —→ ADRs such as dry cough and angioedema

72
New cards

DDI for ACEi

Increased risk of hyperkalemia and/or angioedema in combination with other RAAS inhibitors

73
New cards

Pearls of ACEi

If side effects like dry cough develop, try and ARB instead

74
New cards

ACEi examples:

Lisinopril, enalapril, ramipril, quinapril, benazepril, fosinopril

75
New cards

Brand name of valsartan

Diovan

76
New cards

Indication for ARBs

First-line antihypertensive

Other: MI, heart failure with reduced ejection fraction (HFrEF)

77
New cards

MOA for ARBs

Selective, reversible competitive antagonist of angiotensin II receptor. The angiotensin II receptor is responsible for vasoconstriction, aldosterone secretion, sympathetic outflow, and stimulation of renal sodium reabsorption.

78
New cards

CI for ARBs

Pregnancy

79
New cards

ADRs for ARBs

hyperkalemia, AKI, dizziness, angioedema, rhabdomyolysis,

80
New cards

Key PKPD parameters for ARBs

Since they do not impact bradykinin breakdown, no incidence of dry cough, and a very low risk of angioedema

81
New cards

DDI for ARBs

Increased risk of hyperkalemia and/or angioedema in combination with other RAAS inhibitors

82
New cards

Pearls for ARBs

May use first if trying to prevent side effects like dry cough

83
New cards

ARB examples:

valsartan, irbesartan, losartan, candesartan, Olmesartan, telmisartan

84
New cards

Brand name of amlodipine

Norvasc

85
New cards

Brand name of nifedipine

Procardia

86
New cards

Examples of DHP CCBs?

Amlodipine, felodipine, and nifedipine

87
New cards

Indication for DHP CCBs

first-line antihypertensives

Others: anti-anginal

88
New cards

MOA for DHP CCBs

Inhibits calcium ions from entering slow channels of vascular smooth muscle during depolarization leading to vascular smooth muscle relaxation (vasodilation)

89
New cards

ADRs for DHP CCBs

Peripheral edema, pulmonary edema, hepatotoxicity, thrombocytopenia

90
New cards

Key PKPD for DHP CCBs

May cause reflex sympathetic activation —→ slight tachycardia and increase in cardiac output.

Amlodipine may take up to one week to see full BP lowering effects (half-life of 30-50 hours)

91
New cards

DDI for DHP CCBs

Major substrate of CYP3A4

92
New cards

Key counseling points for DHP CCBs

Immediate release nifedipine has an increased risk of MI and mortality. ONLY USE EXTENDED RELEASE

93
New cards

Brand name of diltiazem

Cardizem

94
New cards

Brand name of verapamil

Calan

95
New cards

Examples of Non-DHP CCBs

Diltiazem, Verapamil

96
New cards

Indication for Non-DHP CCBs

first-line antihypertensive

Other: angina, atrial arrhythmia

97
New cards

MOA of Non-DHP CCB

Inhibits calcium ions from entering slow channels of vascular smooth muscle and myocardium during depolarization leading to vascular smooth muscle relaxation (vasodilation) and slows automaticity of AV node (decreases HR)

98
New cards

CI for Non-DHP CCBs

2nd or 3rd degree heart block

99
New cards

ADRs for Non-DHP CCBs

Peripheral edema, pulmonary edema, headache, heart failure, heart block, hepatotoxicity

100
New cards

Key PKPD for Non-DHP CCBs

Verapamil has the greatest depressant effect on the sympathetic nervous system (HR/CO)

Diltiazem has modest effects